Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRITICS-II preoperative treatment selection trial in resectable gastric cancer
NL-OMON60542Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Event-free survival at 1 year after randomisation. Started Oct 2017; status: active, not recruiting.
02
Drugs
capecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON60542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60542.